Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Cornell University · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Abstract
Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given that patients with advanced melanoma are living longer than 7.5 years, longer-term data were needed to address new clinically relevant questions.
mutation status, metastasis stage, and programmed death ligand 1 expression. Here, we report the final, 10-year results of this trial, including results for overall survival and melanoma-specific survival, as well as durability of response.
Citation impact
- FWCI
- 111.55
- Percentile
- 100%
- References
- 22
Authors
32- JDJedd D. WolchokCorresponding
Cornell University, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
- VCVanna Chiarion‐Sileni
Cornell University, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
- PRPiotr Rutkowski
Cornell University, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
- CLC. Lance Cowey
Cornell University, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
- DSDirk Schadendorf
Cornell University, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Topics & keywords
- Ipilimumab
- Nivolumab
- Medicine
- Melanoma
- Oncology
- Internal medicine
- Immunotherapy
- Cancer research
- Zero hunger